In this article, we focused on the aberrant IDH signaling pathway, reviewing its biological relevance in cancer together with the preclinical and clinical development of selective IDH inhibitors as well as future perspectives in cholangiocarcinoma. The gene discussed is IDH1; the disease is cancer.